Great Northern Minerals (ASX:GNM) unveils a maiden Nevada resource containing 480,000 ounces of gold and 11.5 million ounces of silver, with drilling planned for Q3 2026.
Elevra Lithium (ASX: ELV) has secured a A$441 million financing package to expand its North American lithium operations, backed by strong institutional demand and strategic support from the Canada Growth Fund.
NexGen Energy secures final federal approval for the Rook I uranium project in Canada. Construction of the world’s largest uranium mine is set to begin in 2026.
ASX market wrap for January 5, 2026. Australian shares finish flat as oil prices fall despite US action in Venezuela. Gold and materials lead gains while tech stocks retreat.
Immutep secures a global licensing deal with Dr. Reddy’s for immunotherapy efti, triggering a 25 percent share price jump. Here’s what the partnership means for investors and upcoming clinical milestones.
Lithium prices hit new cycle highs as ASX lithium stocks rally. Pilbara Minerals, IGO, Liontown, Core Lithium and Lake Resources surge as demand from China strengthens and spodumene prices rise sharply.
ASX 200 flat on July 11 as mining stocks offset tariff fears. Materials lead gains amid U.S. rare earth investment; Trump’s Canada tariffs spark global trade unease. Full market breakdown.
Krakatoa Resources (ASX: KTA) advances its Zopkhito project in Georgia with an 11.6% antimony and 3.7g/t gold resource. As global antimony demand surges, KTA targets fast-tracked drilling, JORC conversion, and strategic offtake opportunities.
.png&w=3840&q=75)
Laramide Resources stock up 1.47% after its La Jara Mesa Uranium Project secures U.S. critical minerals designation, streamlining federal permitting and highlighting strategic uranium potential.
%252520Surges%25252042%252520%252520After%252520FDA%252520Greenlights%252520Phase%2525203%252520Trials%252520for%252520Elate%252520Ocular%2525C2%2525AE.webp&w=3840&q=75)
Cambium Bio (ASX: CMB) stock surges 42% after FDA approves Phase 3 trials for Elate Ocular®, its groundbreaking regenerative dry eye treatment. Trial enrolment begins mid-2025—is this the start of a biotech breakout?
Explore how the 2024 U.S. presidential election could influence ASX markets. From potential shifts in gold and bonds to impacts on Australian stocks, learn what a Trump or Harris victory means for investors
Discover why ASX uranium stocks like Boss Energy are primed for explosive growth as nuclear power demand surges. Learn how rising uranium prices, AI-driven energy needs, and clean energy goals are driving investor interest in uranium stocks on the ASX
Great Northern Minerals (ASX:GNM) unveils a maiden Nevada resource containing 480,000 ounces of gold and 11.5 million ounces of silver, with drilling planned for Q3 2026.
Elevra Lithium (ASX: ELV) has secured a A$441 million financing package to expand its North American lithium operations, backed by strong institutional demand and strategic support from the Canada Growth Fund.
NexGen Energy secures final federal approval for the Rook I uranium project in Canada. Construction of the world’s largest uranium mine is set to begin in 2026.
Recce Pharmaceuticals (ASX:RCE) wins Family 4 patent in Hong Kong for RECCE® 327 and 529, expanding IP across Asia as Phase 3 trials continue in Indonesia. CEO James Graham explains the strategic importance and next steps.
%252520Receives%252520Takeover%252520Proposal%252520from%252520U.S.%252520Antimony%252520Corporation%252520(NYSE%252520UAMY).webp&w=3840&q=75)
U.S. Antimony Corporation has submitted a non-binding proposal to acquire Larvotto Resources (ASX: LRV), aiming to form one of the largest antimony producers outside China.
NH3 signs MoU with MOL and Oceania to build clean ammonia bunkering at Dampier by 2030; targets 300ktpa demand and late-2026 FID for WAH2.
%252520(1)%252520(1).png&w=3840&q=75)
